JP2019511214A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511214A5 JP2019511214A5 JP2018545335A JP2018545335A JP2019511214A5 JP 2019511214 A5 JP2019511214 A5 JP 2019511214A5 JP 2018545335 A JP2018545335 A JP 2018545335A JP 2018545335 A JP2018545335 A JP 2018545335A JP 2019511214 A5 JP2019511214 A5 JP 2019511214A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- variant
- fragment
- cancer
- cell receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 53
- 239000012634 fragment Substances 0.000 claims 24
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 19
- 206010028980 Neoplasm Diseases 0.000 claims 18
- 239000003446 ligand Substances 0.000 claims 18
- 108091008874 T cell receptors Proteins 0.000 claims 15
- 210000001519 tissue Anatomy 0.000 claims 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 108091023037 Aptamer Proteins 0.000 claims 5
- 239000013604 expression vector Substances 0.000 claims 5
- 230000014509 gene expression Effects 0.000 claims 5
- 230000005847 immunogenicity Effects 0.000 claims 5
- 238000000338 in vitro Methods 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 239000012528 membrane Substances 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 238000010195 expression analysis Methods 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 238000002659 cell therapy Methods 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 238000012163 sequencing technique Methods 0.000 claims 3
- 102000043129 MHC class I family Human genes 0.000 claims 2
- 108091054437 MHC class I family Proteins 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 238000002493 microarray Methods 0.000 claims 2
- 230000002018 overexpression Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 229920002477 rna polymer Polymers 0.000 claims 2
- 238000010186 staining Methods 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 108700012359 toxins Proteins 0.000 claims 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 238000011510 Elispot assay Methods 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 108010028930 invariant chain Proteins 0.000 claims 1
- 239000012931 lyophilized formulation Substances 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229940038309 personalized vaccine Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 238000012070 whole genome sequencing analysis Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023053020A JP2023093483A (ja) | 2016-03-08 | 2023-03-29 | 子宮がん治療法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662305222P | 2016-03-08 | 2016-03-08 | |
| GB1603987.7 | 2016-03-08 | ||
| GBGB1603987.7A GB201603987D0 (en) | 2016-03-08 | 2016-03-08 | Uterine cancer treatments |
| US62/305,222 | 2016-03-08 | ||
| PCT/EP2017/054908 WO2017153247A1 (en) | 2016-03-08 | 2017-03-02 | Uterine cancer treatments |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023053020A Division JP2023093483A (ja) | 2016-03-08 | 2023-03-29 | 子宮がん治療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019511214A JP2019511214A (ja) | 2019-04-25 |
| JP2019511214A5 true JP2019511214A5 (OSRAM) | 2020-04-16 |
Family
ID=55859178
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545335A Pending JP2019511214A (ja) | 2016-03-08 | 2017-03-02 | 子宮がん治療法 |
| JP2023053020A Pending JP2023093483A (ja) | 2016-03-08 | 2023-03-29 | 子宮がん治療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023053020A Pending JP2023093483A (ja) | 2016-03-08 | 2023-03-29 | 子宮がん治療法 |
Country Status (24)
| Country | Link |
|---|---|
| US (9) | US10138287B2 (OSRAM) |
| EP (2) | EP4491191A3 (OSRAM) |
| JP (2) | JP2019511214A (OSRAM) |
| KR (2) | KR20230019501A (OSRAM) |
| CN (2) | CN118894905A (OSRAM) |
| AR (1) | AR108035A1 (OSRAM) |
| AU (2) | AU2017229149B2 (OSRAM) |
| BR (1) | BR112018015545A2 (OSRAM) |
| CA (1) | CA3015932A1 (OSRAM) |
| CL (3) | CL2018002508A1 (OSRAM) |
| CO (1) | CO2018010284A2 (OSRAM) |
| CR (3) | CR20210038A (OSRAM) |
| EA (1) | EA201891994A1 (OSRAM) |
| ES (1) | ES3005964T3 (OSRAM) |
| GB (1) | GB201603987D0 (OSRAM) |
| IL (1) | IL261468A (OSRAM) |
| MA (2) | MA43466A1 (OSRAM) |
| MX (2) | MX2018010779A (OSRAM) |
| MY (1) | MY189796A (OSRAM) |
| PE (1) | PE20181490A1 (OSRAM) |
| PH (2) | PH12022551120A1 (OSRAM) |
| SG (2) | SG10202008070XA (OSRAM) |
| TW (2) | TWI771694B (OSRAM) |
| WO (1) | WO2017153247A1 (OSRAM) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| ES2898210T3 (es) | 2017-07-14 | 2022-03-04 | Immatics Biotechnologies Gmbh | Molécula de polipéptido con especificidad dual mejorada |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| MX2020008327A (es) | 2018-02-09 | 2020-10-28 | Immatics Us Inc | Metodos para preparar celulas t. |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| PE20220164A1 (es) | 2019-05-27 | 2022-01-28 | Immatics Us Inc | Vectores viricos y uso de los mismos en terapias celulares adoptivas |
| AU2020286756A1 (en) | 2019-06-06 | 2022-01-27 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| AU2021225817A1 (en) | 2020-02-24 | 2022-10-20 | Immatics US, Inc. | Methods for expanding T cells for the treatment of cancer and related malignancies |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| TW202241938A (zh) | 2020-12-31 | 2022-11-01 | 美商英麥提克斯股份有限公司 | Ｃｄ８多肽、組合物及其使用方法 |
| JP2024516699A (ja) | 2021-05-05 | 2024-04-16 | イマティクス バイオテクノロジーズ ゲーエムベーハー | Ｂｍａ０３１抗原結合ポリペプチド |
| US20240358831A1 (en) | 2021-08-24 | 2024-10-31 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
| TW202332765A (zh) | 2021-09-20 | 2023-08-16 | 美商英麥提克斯股份有限公司 | 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡 |
| US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| JP2025515603A (ja) | 2022-04-28 | 2025-05-20 | イマティクス ユーエス，アイエヌシー． | Ｉｌ－１２ポリペプチド、ｉｌ－１５ポリペプチド、ｉｌ－１８ポリペプチド、ｃｄ８ポリペプチド、それらの組成物、およびそれらの使用方法 |
| EP4514834A1 (en) | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| JP2025516189A (ja) | 2022-04-28 | 2025-05-27 | イマティクス ユーエス，アイエヌシー． | 膜結合型ｉｌ－１５、ｃｄ８ポリペプチド、細胞、組成物、およびそれらの使用方法 |
| CN114908167A (zh) * | 2022-05-04 | 2022-08-16 | 重庆大学附属肿瘤医院 | Svil表达水平检测试剂在制备卵巢癌干性诊断试剂中的应用 |
| US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
| CN116024341B (zh) * | 2022-11-25 | 2024-08-30 | 重庆医科大学 | 乳腺癌标志物及其应用 |
| WO2025096649A1 (en) | 2023-11-01 | 2025-05-08 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| IE53176B1 (en) | 1978-12-22 | 1988-08-17 | Biogen Nv | Recombinant dna molecules and their method of production |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| US5283190A (en) | 1989-07-31 | 1994-02-01 | Traish Adbulmaged M | Specific monoclonal antibodies against a defined epitope of progesterone receptor and methods for their use |
| ATE157100T1 (de) | 1993-06-03 | 1997-09-15 | Therapeutic Antibodies Inc | Antikoerperfragmente in therapie |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| DE69723230T2 (de) | 1996-01-17 | 2004-05-27 | Imperial College Innovations Ltd. | Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl) |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| AU785493B2 (en) | 2000-03-27 | 2008-01-03 | Technion Research & Development Foundation Ltd. | Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| CN101712721A (zh) | 2000-06-05 | 2010-05-26 | 阿尔托生物科学有限公司 | T细胞受体融合物及共轭物以及其使用方法 |
| FR2823221B1 (fr) | 2001-04-06 | 2004-04-02 | Univ Pasteur | Sequences associees a la degenerescence retinienne et applications |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| WO2003070752A2 (en) | 2002-02-20 | 2003-08-28 | Dyax Corporation | Mhc-peptide complex binding ligands |
| WO2004033685A1 (en) | 2002-10-09 | 2004-04-22 | Avidex Ltd | Single chain recombinant t cell receptors |
| NZ570811A (en) | 2002-11-09 | 2009-11-27 | Immunocore Ltd | T cell receptor display |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| KR100739118B1 (ko) * | 2005-07-22 | 2007-07-13 | 이제호 | Ｍｓｘ1 단백질 또는 이를 코딩하는 유전자의 신규한 용도 |
| JP4926966B2 (ja) * | 2005-08-18 | 2012-05-09 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ドーパミン産生ニューロン増殖前駆細胞マーカーＭｓｘ１／２ |
| DE602005020046D1 (de) | 2005-09-05 | 2010-04-29 | Immatics Biotechnologies Gmbh | Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden |
| CN1920036A (zh) * | 2006-03-29 | 2007-02-28 | 山东中医药大学 | 猕猴孕酮受体基因片段及其应用 |
| US20080107668A1 (en) * | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| PL2562182T3 (pl) * | 2007-07-27 | 2016-03-31 | Immatics Biotechnologies Gmbh | Nowe immunogenne epitopy do immunoterapii |
| US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
| US9439944B2 (en) * | 2008-04-22 | 2016-09-13 | Sungyunkwan University Foundation For Corporate Collaboration | Agent that inhibits angiogenesis and metastasis targeting mTOR signaling pathway |
| RS53782B1 (sr) * | 2008-10-01 | 2015-06-30 | Immatics Biotechnologies Gmbh | Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera |
| TWI404748B (zh) | 2009-11-10 | 2013-08-11 | Enrestec Inc | 連續式裂解系統及其應用 |
| GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| GB201009222D0 (en) | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
| CA2816225A1 (en) | 2010-10-26 | 2012-05-03 | Technion Research & Development Foundation Ltd. | Antibodies which bind soluble t-cell receptor ligands |
| NZ609916A (en) * | 2010-12-14 | 2015-03-27 | Immatics Biotechnologies Gmbh | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
| WO2014011465A2 (en) * | 2012-07-13 | 2014-01-16 | Albert Einstein College Of Medicine Of Yeshiva University | Aptamer-targeted antigen delivery |
| US20190292535A1 (en) | 2012-11-08 | 2019-09-26 | Roche Diagnostics Operations, Inc. | Nucleic acids encoding chimeric polypeptides for library screening |
| EP2808392A1 (en) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamers and use of the aptamers in the diagnosis and treatment of cancer |
| TWI819228B (zh) | 2013-08-05 | 2023-10-21 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（八） |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201408255D0 (en) | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
| GB201411037D0 (en) * | 2014-06-20 | 2014-08-06 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL) |
| JP6985153B2 (ja) | 2015-05-06 | 2021-12-22 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 結腸直腸がん（ｃｒｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチドとそのスキャフォールドとの組み合わせ |
| MY199262A (en) | 2015-08-28 | 2023-10-23 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
-
2016
- 2016-03-08 GB GBGB1603987.7A patent/GB201603987D0/en not_active Ceased
-
2017
- 2017-03-02 CR CR20210038A patent/CR20210038A/es unknown
- 2017-03-02 KR KR1020237002840A patent/KR20230019501A/ko not_active Ceased
- 2017-03-02 MY MYPI2018703020A patent/MY189796A/en unknown
- 2017-03-02 SG SG10202008070XA patent/SG10202008070XA/en unknown
- 2017-03-02 EA EA201891994A patent/EA201891994A1/ru unknown
- 2017-03-02 SG SG11201807300PA patent/SG11201807300PA/en unknown
- 2017-03-02 CA CA3015932A patent/CA3015932A1/en active Pending
- 2017-03-02 PH PH1/2022/551120A patent/PH12022551120A1/en unknown
- 2017-03-02 WO PCT/EP2017/054908 patent/WO2017153247A1/en not_active Ceased
- 2017-03-02 JP JP2018545335A patent/JP2019511214A/ja active Pending
- 2017-03-02 BR BR112018015545-4A patent/BR112018015545A2/pt not_active IP Right Cessation
- 2017-03-02 MA MA43466A patent/MA43466A1/fr unknown
- 2017-03-02 CN CN202410747770.6A patent/CN118894905A/zh active Pending
- 2017-03-02 EP EP24020331.5A patent/EP4491191A3/en active Pending
- 2017-03-02 EP EP17709931.4A patent/EP3426281B1/en active Active
- 2017-03-02 KR KR1020187028243A patent/KR102493344B1/ko active Active
- 2017-03-02 CR CR20210036A patent/CR20210036A/es unknown
- 2017-03-02 PE PE2018001580A patent/PE20181490A1/es unknown
- 2017-03-02 AU AU2017229149A patent/AU2017229149B2/en not_active Ceased
- 2017-03-02 CR CR20180460A patent/CR20180460A/es unknown
- 2017-03-02 MX MX2018010779A patent/MX2018010779A/es unknown
- 2017-03-02 ES ES17709931T patent/ES3005964T3/es active Active
- 2017-03-02 CN CN201780016147.1A patent/CN109475596B/zh active Active
- 2017-03-02 MA MA049295A patent/MA49295A/fr unknown
- 2017-03-06 US US15/451,167 patent/US10138287B2/en active Active
- 2017-03-08 TW TW109119177A patent/TWI771694B/zh not_active IP Right Cessation
- 2017-03-08 TW TW106107560A patent/TWI731945B/zh not_active IP Right Cessation
- 2017-03-08 AR ARP170100576A patent/AR108035A1/es not_active Application Discontinuation
-
2018
- 2018-08-28 PH PH12018501828A patent/PH12018501828A1/en unknown
- 2018-08-29 IL IL261468A patent/IL261468A/en unknown
- 2018-09-03 CL CL2018002508A patent/CL2018002508A1/es unknown
- 2018-09-06 MX MX2022003884A patent/MX2022003884A/es unknown
- 2018-09-26 CO CONC2018/0010284A patent/CO2018010284A2/es unknown
- 2018-10-08 US US16/154,457 patent/US10669325B2/en not_active Expired - Fee Related
- 2018-11-02 US US16/178,672 patent/US10239932B2/en active Active
- 2018-11-02 US US16/178,674 patent/US10266581B2/en active Active
-
2019
- 2019-03-11 US US16/298,652 patent/US20190194289A1/en not_active Abandoned
- 2019-11-12 US US16/680,634 patent/US11390660B2/en active Active
-
2020
- 2020-07-20 CL CL2020001897A patent/CL2020001897A1/es unknown
- 2020-07-20 CL CL2020001898A patent/CL2020001898A1/es unknown
-
2021
- 2021-06-04 US US17/339,371 patent/US12221467B2/en active Active
- 2021-06-11 US US17/345,553 patent/US12234276B2/en active Active
- 2021-07-26 AU AU2021207620A patent/AU2021207620A1/en not_active Abandoned
-
2023
- 2023-03-29 JP JP2023053020A patent/JP2023093483A/ja active Pending
-
2025
- 2025-01-07 US US19/012,311 patent/US20250145686A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019511214A5 (OSRAM) | ||
| JP2021168652A5 (OSRAM) | ||
| JP2019502360A5 (OSRAM) | ||
| JP2019506838A5 (OSRAM) | ||
| JP2024099580A5 (OSRAM) | ||
| JP2019510465A5 (OSRAM) | ||
| JP2018510628A5 (OSRAM) | ||
| JP2024041841A5 (OSRAM) | ||
| JP2018529320A5 (OSRAM) | ||
| JP2018536383A5 (OSRAM) | ||
| JP2018509135A5 (OSRAM) | ||
| JP2018519243A5 (OSRAM) | ||
| JP2018520653A5 (OSRAM) | ||
| RU2017137142A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| JP2018511321A5 (OSRAM) | ||
| JP2018518937A5 (OSRAM) | ||
| JP2017525336A5 (OSRAM) | ||
| JP2017502076A5 (OSRAM) | ||
| JP2020191862A5 (OSRAM) | ||
| JP2020182458A5 (OSRAM) | ||
| JP2020198875A5 (OSRAM) | ||
| HRP20202019T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora | |
| JP2019516663A5 (OSRAM) | ||
| JP2018518956A5 (OSRAM) | ||
| JP2018521641A5 (OSRAM) |